Medscape9d
Male Bone Health at Risk in Congenital Adrenal Hyperplasia
Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...
The Lancet6d
A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia
On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies ...
Neurocrine Biosciences To Present At The Stifel 2025 Virtual CNS Forum
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...
Contract Pharma14d
HBM Alpha Therapeutics Strikes $395M Deal for CRH Antibody Therapy
Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder ...
BioSpace6d
Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...